Phreesia, Inc. (NYSE:PHR – Get Free Report) SVP Amy Beth Vanduyn sold 1,311 shares of Phreesia stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $26.61, for a total value of $34,885.71. Following the sale, the senior vice president now directly owns 115,633 shares in the company, valued at $3,076,994.13. The trade was a 1.12 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Amy Beth Vanduyn also recently made the following trade(s):
- On Tuesday, December 3rd, Amy Beth Vanduyn sold 25,447 shares of Phreesia stock. The stock was sold at an average price of $20.93, for a total value of $532,605.71.
Phreesia Price Performance
Phreesia stock opened at $28.42 on Friday. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $29.16. The firm has a market cap of $1.65 billion, a P/E ratio of -19.33 and a beta of 0.94. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.77 and a current ratio of 1.74. The business’s fifty day moving average is $22.70 and its two-hundred day moving average is $22.57.
Institutional Trading of Phreesia
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Franklin Resources Inc. boosted its position in Phreesia by 3.0% in the 3rd quarter. Franklin Resources Inc. now owns 1,497,631 shares of the company’s stock valued at $31,495,000 after buying an additional 42,973 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Phreesia by 4.7% in the third quarter. Geode Capital Management LLC now owns 1,245,797 shares of the company’s stock valued at $28,397,000 after acquiring an additional 55,934 shares during the last quarter. M&T Bank Corp increased its position in Phreesia by 4.6% in the third quarter. M&T Bank Corp now owns 35,127 shares of the company’s stock worth $801,000 after purchasing an additional 1,535 shares during the period. Barclays PLC increased its position in Phreesia by 83.6% in the third quarter. Barclays PLC now owns 94,929 shares of the company’s stock worth $2,163,000 after purchasing an additional 43,225 shares during the period. Finally, XTX Topco Ltd bought a new stake in Phreesia during the 3rd quarter worth about $247,000. Institutional investors and hedge funds own 92.10% of the company’s stock.
Wall Street Analyst Weigh In
A number of equities analysts have recently issued reports on PHR shares. JMP Securities restated a “market outperform” rating and issued a $30.00 price objective on shares of Phreesia in a research note on Tuesday, December 10th. Robert W. Baird cut their price target on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Truist Financial lifted their price objective on Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Royal Bank of Canada raised Phreesia from a “sector perform” rating to an “outperform” rating and increased their target price for the stock from $24.00 to $32.00 in a report on Wednesday. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $29.00 price target on shares of Phreesia in a research note on Tuesday, December 10th. Eleven research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $30.64.
Check Out Our Latest Report on Phreesia
Phreesia Company Profile
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
Recommended Stories
- Five stocks we like better than Phreesia
- How to Calculate Stock Profit
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- Stock Splits, Do They Really Impact Investors?
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.